Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Aeglea BioTherapeutics, Inc. | agle-ex322_546.htm |
| EX-32.1 - EX-32.1 - Aeglea BioTherapeutics, Inc. | agle-ex321_545.htm |
| EX-31.2 - EX-31.2 - Aeglea BioTherapeutics, Inc. | agle-ex312_544.htm |
| EX-31.1 - EX-31.1 - Aeglea BioTherapeutics, Inc. | agle-ex311_543.htm |
| EX-10.20 - EX-10.20 - Aeglea BioTherapeutics, Inc. | agle-ex1020_1043.htm |
| EX-10.19 - EX-10.19 - Aeglea BioTherapeutics, Inc. | agle-ex1019_1042.htm |
| EX-10.13 - EX-10.13 - Aeglea BioTherapeutics, Inc. | agle-ex1013_777.htm |
| 10-K - 10-K - Aeglea BioTherapeutics, Inc. | agle-10k_20161231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Form S‑8 (No. 333-210633) of Aeglea BioTherapeutics, Inc. of our report dated March 23, 2017 relating to the financial statements, which appears in this Form 10‑K.
/s/ PricewaterhouseCoopers LLP
Austin, Texas
March 23, 2017